UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2006
Three months
Nine Months
Year
PARTICULARS
ended
31.12.06
31.12.05
31.03.06
Unaudited
Audited
Net Sales/Operational Income
9530.83
8235.49
22115.43
24260.56
32341.62
Others Income
9.57
34.09
444.47
98.05
103.41
TOTAL EXPENDITURE :
7953.68
6571.64
18303.41
19631.68
26300.61
(a) (Increase)/decrease in stock in trade
(33.36)
(36.19)
(761.50)
(878.48)
(1595.27)
(b) Consumption of Raw Material
6416.44
5013.78
14178.53
16202.08
22070.92
(c) Staff Cost
231.31
189.76
624.78
479.77
640.02
(d) Other expenditure
1339.29
1404.28
4261.61
3828.32
5184.93
Interest
605.82
299.83
1630.47
815.46
1245.20
Depreciation
307.24
233.02
880.51
582.74
810.88
Profit before tax
673.66
1165.10
1745.52
3328.74
4088.34
Provision for taxation
84.96
98.04
220.60
280.11
361.14
Provision for fringe benefit tax
2.03
1.55
7.48
4.55
6.38
Net Profit before Deferred Tax
586.66
1065.50
1517.43
3044.08
3720.82
Provision for deferred tax
35.02
155.11
92.17
302.24
242.14
Net Profit
551.65
910.40
1425.25
2741.84
3478.68
Paid up Equity Share Capital
2250.10
2090.00
2152.00
Reserve excluding revaluation reserves
19234.72
15802.56
16810.23
EPS Rs. (Not Annualized) Basic
2.50
4.69
6.45
14.14
17.52
4.40
13.26
17.00
Aggregated on Non-Promoters Shareholding
15704594
15504594
69.80%
74.18%
72.05%
1
The previous period figures have been re-grouped and re-arranged wherever necessary.
2
The Company is exclusively in the Pharmaceutical business segment.
3
Information on Investor Complaints for the quarter: Opening Balance Nil, Received 11, Redressed 11, closing Balance Nil.
4
The above results were taken on record by the Board of Directors in its meeting held on 24th January, 2007.
